AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve rapidly with significant developments in drug approvals, regulatory changes, and innovative therapies. The latest updates highlight the tension between scientific advancement and regulatory scrutiny. A prime example is the FDA's proposal to rescind approval of Amgen's Tavneos due to alleged data manipulation and safety concerns....
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharma and BioTech Daily
Novartis' $23B U.S. Investment Boosts Pharma Manufacturing | Pharma and Biotech Daily
AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily
Sun Pharma's $11.75B Organon Deal: Industry Shockwave | Pharma and Biotech Daily
Merck Unveils PD-1xVEGF Data, Delays Phase 3 Plans | Pharma and Biotech Daily
Get summaries like this every morning.
Free AI-powered recaps of Pharma and BioTech Daily and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.